Literature DB >> 8357052

Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group.

.   

Abstract

The objective of our clinic-based case-control study was to identify risk factors for branch retinal vein occlusion. Between 1986 and 1990 data were obtained at five clinical centers from 270 patients with branch retinal vein occlusion and 1,142 controls. Data were collected from interviews, clinical examinations, and laboratory analyses of blood specimens. An increased risk of branch retinal vein occlusion was found in persons with a history of systemic hypertension, a history of cardiovascular disease, an increased body mass index at 20 years of age, a history of glaucoma, and higher serum levels of alpha 2-globulin. Risk of branch retinal vein occlusion decreased with higher levels of alcohol consumption and high-density lipoprotein cholesterol. The data suggest a cardiovascular risk profile for patients with branch retinal vein occlusion and indicate that 50% of patients with branch retinal vein occlusion may be attributable to hypertension. Our findings support current public health recommendations to diagnose and treat hypertension, reduce weight, increase physical activity, and maximize serum high-density lipoprotein levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357052

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  46 in total

1.  Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Michael S Ip; Barbara A Blodi; Mary Elizabeth Hartnett; Geoff Cohen
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

2.  [Thrombophilic and systemic risk factors in patients with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; W Miesbach; I Scharrer; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

Review 3.  The future of glaucoma clinics.

Authors:  A M S Morley; I Murdoch
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

4.  Bilateral macular hole in a patient with chronic renal failure after recurrent deep vein thrombosis.

Authors:  Zisis Gatzioufas; Matthias Krause; Ursula Löw; Berthold Seitz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-15       Impact factor: 3.117

5.  Arterio-venous dissection after isovolaemic haemodilution in branch retinal vein occlusion: a non-randomised prospective study.

Authors:  Nicolas Feltgen; Julia Herrmann; Hansjuergen Agostini; Adel Sammain; Lutz L Hansen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-09       Impact factor: 3.117

6.  Haemorheology in patients with branch retinal vein occlusion with and without risk factors.

Authors:  A Remky; O Arend; F Jung; H Kiesewetter; M Reim; S Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

7.  Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study.

Authors:  Melissa Mei Hsia Chan; Akshay S Thomas; Stephen P Yoon; Diana Leitner; Sharon Fekrat
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-07-01       Impact factor: 1.300

8.  Measurement of lamina and prelaminar thicknesses of both eyes in patients with unilateral branch retinal vein occlusion.

Authors:  Yengwoo Son; Seungwoo Lee; Jongyeop Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-14       Impact factor: 3.117

9.  Retinal vein occlusion: pathophysiology and treatment options.

Authors:  Niral Karia
Journal:  Clin Ophthalmol       Date:  2010-07-30

10.  Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion.

Authors:  Iris Steinbrugger; Anton Haas; Richard Maier; Wilfried Renner; Monika Mayer; Christoph Werner; Andreas Wedrich; Yosuf El-Shabrawi; Otto Schmut; Martin Weger
Journal:  Mol Vis       Date:  2009-03-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.